Gilead Sciences (GILD) received a major pipeline setback with disappointing results from a phase III trial of darusentan in which it failed to achieve its primary endpoint. The drug was being studied under an international clinical trial (DAR-312) for the treatment of resistant hypertension. As a result of the setback, Gilead is considering the option of dropping the program so that its resources can be utilized for other potential candidates rather than conducting another intensive phase III study.
More
No comments:
Post a Comment